MET and non-small cell lung carcinoma: In particular, while not having a strong clinical impact (CNVs are not still included in NSCLC 2023 ESCAT I-II variants), these new CNV calls could potentially candidate patients for clinical trials [38–41], or unveiling MET amplification as the cause of drug resistance in patients treated for an EGFR common mutation [42].